Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Schistosomiasis vaccine

Bergquist, R., Al-Sherbiny, M., Barakat, R. and Olds, R. (2002) Blueprint for schistosomiasis vaccine development. Acta Tropica 82, 183-192. [Pg.146]

Cryseels, B. (2000) Schistosomiasis vaccines a devils advocate view. Parasitology Today 1 6, 46-48. [Pg.148]

Hagan, P. and Sharaf, O. (2003) Schistosomiasis vaccines. Expert Opinion on Biological Therapy 3, 1271 -1278. [Pg.148]

Hagan, P., Doenhoff, M.J., Wilson, R.A., Al-Sherbiny, M. and Bergquist, R. (2000) Schistosomiasis vaccines a response to a devils advocate s view. Parasitology Today 16, 322-323. [Pg.148]

Wynn, T.A. (1 999) Immune deviation as a strategy for schistosomiasis vaccines designed to prevent infection and egg-induced immunopathology. Microbes and Infection 1, 525-534. [Pg.191]

One likely reason for the prevalence of helminths is their undoubted ability to down-regulate the host immune system at both the antigen-specific and polyclonal levels [3], In many chronic diseases, such as schistosomiasis and lymphatic filariasis, peripheral blood T cells show dramatically impaired parasite antigen-specific responsiveness [4], as discussed in more detail below. Moreover, from early reports of immunosuppression in animal models of infection, to studies in Africa linking vaccine failure to heavy helminth infection, there is clear evidence that infections can diminish reactivity to bystander antigens, particularly with increasing intensity of... [Pg.112]

Grzych, J.M., M. Capron, PH. Lambert, C. Dissous, S. Torres, and A. Capron, An antiidiotype vaccine against experimental schistosomiasis. Nature, 1985. 316(6023) 74-6. [Pg.326]

Schistosomiasis - [ANTIPARASITICAGENTS - ANTHELMINTICS] (Vol 3) - [COPPER] (Vol 7) - [MEMORY-ENHANCINGDRUGS] (Vol 16) -developing vaccines for [VACCINE TECHNOLOGY] (Vol 24) -pesticide control of [PESTICIDES] (Vol 18) -tartar emetic m treatment of [ANTIMONY COMPOUNDS] (Vol 3) -treatment of [ANTIBIOTICS - NUCLEOSIDES AND NUCLEOTIDES] (Vol 3)... [Pg.872]

Lebens, M., Sun, J.B., Czerkinsky, C. and Holmgren, J. (2004) Current status and future prospects for a vaccine against schistosomiasis. Expert Review of Vaccines 3, 315-328. [Pg.170]

Pearce, E.J. (2003) Progress towards a vaccine for schistosomiasis. Acta Tropica 86, 309-313. [Pg.171]

Todd, C.W. and Colley, D.C. (2002) Practical and ethical issues in the development of a vaccine against Schistosomiasis mansoni. American Journal of Tropical Medicine and Hygiene 66, 348-358. [Pg.191]

The development of a vaccine would be a significant advance towards reducing the burden of schistosomiasis. However, efforts to develop a molecular-based vaccine for this disease have proven to be a challenging task. Furthermore, the intensity of research towards this worthwhile goal appears to have waned,... [Pg.228]

In the context of schistosomiasis, where parasites do not multiply in the mammalian host, protective immunity is primarily measured as a reduction in the adult worm burden of vaccinated animals relative to controls. Conventionally, this has been assessed by a terminal procedure involving perfusion of the portal... [Pg.304]

Progress towards human trials raises the thorny question of how to evaluate vaccine success in humans, because protection in experimental animals has almost invariably been measured by worm recovery. One exception was the small-scale attenuated vaccine trial in chimpanzees (Eberl et a/., 2001), where estimates of protection were based on faecal egg output and circulating antigen levels but could not be validated against worm burden for ethical reasons. More recently, these indirect estimators of worm burden have been evaluated with respect to actual recoveries in baboons exposed to the attenuated vaccine, revealing their significant overestimation of protection levels (Kariuki et al., 2004). This issue needs to be addressed before we proceed to full-scale vaccine trials for schistosomiasis mansoni but may be less crucial for schistosomiasis haematobia where egg output in the urine is easier to measure. [Pg.313]

Capron, A., Capron, M. and Riveau, G. (2002) Vaccine development against schistosomiasis from concepts to clinical trials. British Medical Bulletin 62, 139-148. [Pg.318]

Crzych, J.M., Capron, M., Lambert, P.H., Dissous, C., Torres, S. and Capron, A. (1 985) An anti-idiotype vaccine against experimental schistosomiasis. Nature 316, 74-76. [Pg.320]

James, S.L. and Pearce, E.J. (1 988) The influence of adjuvant on induction of protective immunity by a nonliving vaccine against schistosomiasis. The Journal of Immunology 1 40, 2753-2759. [Pg.321]

Kresina, T.F. and Olds, G.R. (1 989) Antiidiotypic antibody vaccine in murine schistosomiasis mansoni comprising the internal image of antigen. The Journal of Clinical Investigation 83, 912-920. [Pg.321]

Tendler, M., Pinto, R.M., Lima Ade, O., Savino, W. and Katz, N. (1 991) Vaccination in murine schistosomiasis with adult worm-derived antigens variables influencing protection in outbred mice. International... [Pg.324]

See other pages where Schistosomiasis vaccine is mentioned: [Pg.191]    [Pg.303]    [Pg.304]    [Pg.304]    [Pg.325]    [Pg.459]    [Pg.191]    [Pg.303]    [Pg.304]    [Pg.304]    [Pg.325]    [Pg.459]    [Pg.358]    [Pg.360]    [Pg.60]    [Pg.230]    [Pg.1659]    [Pg.1660]    [Pg.144]    [Pg.152]    [Pg.181]    [Pg.184]    [Pg.184]    [Pg.184]    [Pg.229]    [Pg.269]    [Pg.304]    [Pg.313]    [Pg.320]    [Pg.410]   
See also in sourсe #XX -- [ Pg.46 , Pg.58 , Pg.75 , Pg.81 , Pg.84 , Pg.152 , Pg.228 , Pg.229 , Pg.269 , Pg.303 , Pg.304 , Pg.305 , Pg.306 , Pg.307 , Pg.308 , Pg.309 , Pg.310 , Pg.311 , Pg.312 , Pg.313 , Pg.314 , Pg.315 , Pg.316 , Pg.363 ]



SEARCH



Schistosomiasis

© 2024 chempedia.info